BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncologyfocused contract research organization (“CRO”).
“Our partnership will enable customers to benefit from Kaizen’s expertise in worldwide oncology trials and BioClinica’s best-in-class product suite offering,” said Peter Benton, President of the eClinical Division of BioClinica. “Kaizen’s oncology focus makes it a strong addition to the BioClinica Certified Partner Program, supporting customers in the complex therapeutic areas of study monitoring and management.”
The BioClinica Certified Partner (“BCP”) Program helps CROs address many of the complexities associated with clinical trials by leveraging the focus and the power of BioClinica software and services. BioClinica solutions enable CROs to start clinical studies more efficiently, optimize data collection, to ensure timely grants payments and track performance. BioClinica solutions provide CROs with the optimal means to more efficiently manage multiple studies with multiple sponsors and to supplement their therapeutic and clinical expertise with BioClinica’s global clinical technology support.
Kaizen Clinical Services, based in Jackson, New Jersey, is a woman-owned contract research organization that focuses on oncology trials. Founded in 2007, Kaizen offers project management, clinical monitoring, consulting and training services. The firm has managed and/or monitored Phase I through Phase IV trials that have enrolled between 35 and 2,500 patients.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.